Isoprinosine abolishes the blocking factor-mediated inhibition of lymphocyte responses to Epstein-Barr virus antigens and phytohemagglutinin.
Acute infectious mononucleosis (IM) is accompanied by measurable abnormalities of immune function, including a transient immunosuppression. The sera of patients with acute IM contain an IgG blocking factor which binds to T-lymphocytes and decreases their responses to antigens and mitogens. The experiments reported herein indicate that isoprinosine, an immunopotentiating agent, can reverse this inhibition of T cells by IM-associated IgG blocking factor. Isoprinosine may be a useful tool in understanding the interactions between blocking factors and lymphocytes; moreover, isoprinosine may be of value in patients with abnormal clinical responses to Epstein-Barr virus (EBV) such as chronic IM or persistent active EBV infections.
Sundar
S K
SK
Menezes
J
J
D000956:Antigens, Viral / Q000276:immunology; D002478:Cells, Cultured; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis / Q000037:antagonists & inhibitors; D007244:Infectious Mononucleosis / Q000276:immunology; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000276:immunology / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D010835:Phytohemagglutinins / Q000276:immunology*
D000956:Antigens, Viral; D007074:Immunoglobulin G; D010835:Phytohemagglutinins; D007288:Inosine; D007542:Inosine Pranobex